168 related articles for article (PubMed ID: 35600400)
1. Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh Class A Liver function: A Pilot Study.
Wang F; Numata K; Komiyama S; Miwa H; Sugimori K; Ogushi K; Moriya S; Nozaki A; Chuma M; Ruan L; Maeda S
Front Oncol; 2022; 12():843680. PubMed ID: 35600400
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anti-PD-1 monotherapy
Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
[TBL] [Abstract][Full Text] [Related]
3. An Investigation of Popping During Radiofrequency Ablation After Lenvatinib Administration for Hepatocellular Carcinoma.
Ishikawa T; Hasegawa I; Hirosawa H; Honmou T; Sakai N; Igarashi T; Yamazaki S; Kobayashi T; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
In Vivo; 2023; 37(2):836-840. PubMed ID: 36881054
[TBL] [Abstract][Full Text] [Related]
4. Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma.
Su CW; Teng W; Lin PT; Jeng WJ; Chen KA; Hsieh YC; Chen WT; Ho MM; Hsieh CH; Wang CT; Chai PM; Lin CC; Lin CY; Lin SM
Cancer Med; 2023 Mar; 12(6):7077-7089. PubMed ID: 36468578
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China.
Zhu Y; Sun P; Wang K; Xiao S; Cheng Y; Li X; Wang B; Li J; Yu W; Cheng Y
Cancer Cell Int; 2021 Sep; 21(1):503. PubMed ID: 34537075
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.
Kudo M; Ueshima K; Chan S; Minami T; Chishina H; Aoki T; Takita M; Hagiwara S; Minami Y; Ida H; Takenaka M; Sakurai T; Watanabe T; Morita M; Ogawa C; Wada Y; Ikeda M; Ishii H; Izumi N; Nishida N
Cancers (Basel); 2019 Jul; 11(8):. PubMed ID: 31370183
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization combined with iodine 125 seeds versus transarterial chemoembolization combined with radiofrequency ablation in the treatment of early- and intermediate-stage hepatocellular carcinoma.
Chen L; Kan X; Sun T; Ren Y; Cao Y; Yan L; Liang B; Xiong B; Zheng C
BMC Gastroenterol; 2020 Jun; 20(1):205. PubMed ID: 32600349
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
[TBL] [Abstract][Full Text] [Related]
10. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.
Chen J; Xiong P; Nie M; Pan Y; Wang J; Hu D; Zhou Z; Zhang Y; Chen M; Xu L
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2491-2500. PubMed ID: 35752744
[TBL] [Abstract][Full Text] [Related]
11. Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.
Yang Y; Yu H; Qi L; Liu C; Feng Y; Qi J; Li J; Zhu Q
Int J Hyperthermia; 2022; 39(1):455-465. PubMed ID: 35271786
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1679. PubMed ID: 35822407
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis.
Shimose S; Kawaguchi T; Tanaka M; Iwamoto H; Miyazaki K; Moriyama E; Suzuki H; Niizeki T; Shirono T; Nakano M; Suga H; Yamaguchi T; Yokokura Y; Noguchi K; Koga H; Torimura T
Oncol Lett; 2020 Sep; 20(3):2257-2265. PubMed ID: 32782543
[TBL] [Abstract][Full Text] [Related]
14. Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization.
Shi Q; Huang P; Zhang Z; Zhang W; Liu L; Yan Z
J Hepatocell Carcinoma; 2023; 10():1861-1871. PubMed ID: 37885925
[TBL] [Abstract][Full Text] [Related]
15. Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Tada T; Kumada T; Hiraoka A; Michitaka K; Atsukawa M; Hirooka M; Tsuji K; Ishikawa T; Takaguchi K; Kariyama K; Itobayashi E; Tajiri K; Shimada N; Shibata H; Ochi H; Yasuda S; Toyoda H; Fukunishi S; Ohama H; Kawata K; Nakamura S; Nouso K; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Joko K; Koizumi Y; Hiasa Y;
Oncology; 2021; 99(8):518-527. PubMed ID: 33906189
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
Ouyang T; Cao Y; Chen L; Zheng C
Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
[TBL] [Abstract][Full Text] [Related]
17. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
[TBL] [Abstract][Full Text] [Related]
18. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
Li Q; Cao M; Yuan G; Cheng X; Zang M; Chen M; Hu X; Huang J; Li R; Guo Y; Ruan J; Chen J
Front Oncol; 2022; 12():809709. PubMed ID: 35280760
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
[TBL] [Abstract][Full Text] [Related]
20. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective study.
Ji X; Xu Z; Sun J; Li W; Duan X; Wang Q
Radiat Oncol; 2023 Jun; 18(1):101. PubMed ID: 37308914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
